Cargando…

Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials

OBJECTIVE: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are emerging. Clinical trials currently rely on invasive biopsies or motivation-dependent functional tests to assess outcome. Quantitative muscle magnetic resonance imaging (MRI) could offer a valuable alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricotti, Valeria, Evans, Matthew R. B., Sinclair, Christopher D. J., Butler, Jordan W., Ridout, Deborah A., Hogrel, Jean-Yves, Emira, Ahmed, Morrow, Jasper M., Reilly, Mary M., Hanna, Michael G., Janiczek, Robert L., Matthews, Paul M., Yousry, Tarek A., Muntoni, Francesco, Thornton, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029878/
https://www.ncbi.nlm.nih.gov/pubmed/27649492
http://dx.doi.org/10.1371/journal.pone.0162542
_version_ 1782454591338577920
author Ricotti, Valeria
Evans, Matthew R. B.
Sinclair, Christopher D. J.
Butler, Jordan W.
Ridout, Deborah A.
Hogrel, Jean-Yves
Emira, Ahmed
Morrow, Jasper M.
Reilly, Mary M.
Hanna, Michael G.
Janiczek, Robert L.
Matthews, Paul M.
Yousry, Tarek A.
Muntoni, Francesco
Thornton, John S.
author_facet Ricotti, Valeria
Evans, Matthew R. B.
Sinclair, Christopher D. J.
Butler, Jordan W.
Ridout, Deborah A.
Hogrel, Jean-Yves
Emira, Ahmed
Morrow, Jasper M.
Reilly, Mary M.
Hanna, Michael G.
Janiczek, Robert L.
Matthews, Paul M.
Yousry, Tarek A.
Muntoni, Francesco
Thornton, John S.
author_sort Ricotti, Valeria
collection PubMed
description OBJECTIVE: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are emerging. Clinical trials currently rely on invasive biopsies or motivation-dependent functional tests to assess outcome. Quantitative muscle magnetic resonance imaging (MRI) could offer a valuable alternative and permit inclusion of non-ambulant DMD subjects. The aims of our study were to explore the responsiveness of upper-limb MRI muscle-fat measurement as a non-invasive objective endpoint for clinical trials in non-ambulant DMD, and to investigate the relationship of these MRI measures to those of muscle force and function. METHODS: 15 non-ambulant DMD boys (mean age 13.3 y) and 10 age-gender matched healthy controls (mean age 14.6 y) were recruited. 3-Tesla MRI fat-water quantification was used to measure forearm muscle fat transformation in non-ambulant DMD boys compared with healthy controls. DMD boys were assessed at 4 time-points over 12 months, using 3-point Dixon MRI to measure muscle fat-fraction (f.f.). Images from ten forearm muscles were segmented and mean f.f. and cross-sectional area recorded. DMD subjects also underwent comprehensive upper limb function and force evaluation. RESULTS: Overall mean baseline forearm f.f. was higher in DMD than in healthy controls (p<0.001). A progressive f.f. increase was observed in DMD over 12 months, reaching significance from 6 months (p<0.001, n = 7), accompanied by a significant loss in pinch strength at 6 months (p<0.001, n = 9) and a loss of upper limb function and grip force observed over 12 months (p<0.001, n = 8). CONCLUSIONS: These results support the use of MRI muscle f.f. as a biomarker to monitor disease progression in the upper limb in non-ambulant DMD, with sensitivity adequate to detect group-level change over time intervals practical for use in clinical trials. Clinical validity is supported by the association of the progressive fat transformation of muscle with loss of muscle force and function.
format Online
Article
Text
id pubmed-5029878
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50298782016-10-10 Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials Ricotti, Valeria Evans, Matthew R. B. Sinclair, Christopher D. J. Butler, Jordan W. Ridout, Deborah A. Hogrel, Jean-Yves Emira, Ahmed Morrow, Jasper M. Reilly, Mary M. Hanna, Michael G. Janiczek, Robert L. Matthews, Paul M. Yousry, Tarek A. Muntoni, Francesco Thornton, John S. PLoS One Research Article OBJECTIVE: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are emerging. Clinical trials currently rely on invasive biopsies or motivation-dependent functional tests to assess outcome. Quantitative muscle magnetic resonance imaging (MRI) could offer a valuable alternative and permit inclusion of non-ambulant DMD subjects. The aims of our study were to explore the responsiveness of upper-limb MRI muscle-fat measurement as a non-invasive objective endpoint for clinical trials in non-ambulant DMD, and to investigate the relationship of these MRI measures to those of muscle force and function. METHODS: 15 non-ambulant DMD boys (mean age 13.3 y) and 10 age-gender matched healthy controls (mean age 14.6 y) were recruited. 3-Tesla MRI fat-water quantification was used to measure forearm muscle fat transformation in non-ambulant DMD boys compared with healthy controls. DMD boys were assessed at 4 time-points over 12 months, using 3-point Dixon MRI to measure muscle fat-fraction (f.f.). Images from ten forearm muscles were segmented and mean f.f. and cross-sectional area recorded. DMD subjects also underwent comprehensive upper limb function and force evaluation. RESULTS: Overall mean baseline forearm f.f. was higher in DMD than in healthy controls (p<0.001). A progressive f.f. increase was observed in DMD over 12 months, reaching significance from 6 months (p<0.001, n = 7), accompanied by a significant loss in pinch strength at 6 months (p<0.001, n = 9) and a loss of upper limb function and grip force observed over 12 months (p<0.001, n = 8). CONCLUSIONS: These results support the use of MRI muscle f.f. as a biomarker to monitor disease progression in the upper limb in non-ambulant DMD, with sensitivity adequate to detect group-level change over time intervals practical for use in clinical trials. Clinical validity is supported by the association of the progressive fat transformation of muscle with loss of muscle force and function. Public Library of Science 2016-09-20 /pmc/articles/PMC5029878/ /pubmed/27649492 http://dx.doi.org/10.1371/journal.pone.0162542 Text en © 2016 Ricotti et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ricotti, Valeria
Evans, Matthew R. B.
Sinclair, Christopher D. J.
Butler, Jordan W.
Ridout, Deborah A.
Hogrel, Jean-Yves
Emira, Ahmed
Morrow, Jasper M.
Reilly, Mary M.
Hanna, Michael G.
Janiczek, Robert L.
Matthews, Paul M.
Yousry, Tarek A.
Muntoni, Francesco
Thornton, John S.
Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
title Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
title_full Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
title_fullStr Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
title_full_unstemmed Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
title_short Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
title_sort upper limb evaluation in duchenne muscular dystrophy: fat-water quantification by mri, muscle force and function define endpoints for clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029878/
https://www.ncbi.nlm.nih.gov/pubmed/27649492
http://dx.doi.org/10.1371/journal.pone.0162542
work_keys_str_mv AT ricottivaleria upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT evansmatthewrb upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT sinclairchristopherdj upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT butlerjordanw upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT ridoutdeboraha upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT hogreljeanyves upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT emiraahmed upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT morrowjasperm upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT reillymarym upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT hannamichaelg upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT janiczekrobertl upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT matthewspaulm upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT yousrytareka upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT muntonifrancesco upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials
AT thorntonjohns upperlimbevaluationinduchennemusculardystrophyfatwaterquantificationbymrimuscleforceandfunctiondefineendpointsforclinicaltrials